Coronary heart disease
Conditions
Interventions
Control group:According to the secondary prevention of coronary heart disease, patients were given health education, adjustment of lifestyle, control of risk factors, such as smoking cessation, contro
Treatment group:Western medicine treatment plan is the same as the control group, Chinese medicine plus Lengzhu granules (vinegar Sanling formula granules 1g, specifications: 1g granules /9g decoction
Vinegar Zedoary (Guangxi Zedoary) formula granules 1g, specifications: 1g granules /8g decoction pieces
Ginger formula granule 6g, specification: 0.5g granule /6g decoction piece
Jujube formula granules 3g, specifications: 2.5g granules /3g decoction pieces
Glycyrrhiza formula granules 3g, specifications: 1g granules /3g decoction pieces
Drug production Company: Jiangyin Tianjiang Pharmaceutical Co., LTD.) Water infusion, 1 dose/day
The course of treatment is 40 days.
Sponsors
Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: (1) Patients diagnosed with coronary heart disease according to Western medicine criteria and diagnosed with chest pain and Qi stagnation and blood stasis pattern according to traditional Chinese medicine. (2) Coronary artery stenosis of 50%-70% determined by coronary CT angiography (CTA) or coronary angiography. (3) Male or female patients aged 18-85 years. (4) Patients with normal communication ability who can cooperate with treatment and follow-up observation. (5) Patients who are informed and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: (1) Any coronary artery lesion exceeding 70%. (2) Vulnerable groups such as pregnant/lactating women. (3) Patients with allergies or allergic reactions to the treatment drugs used in this study. (4) Patients with severe liver, kidney, hematopoietic, or coagulation disorders. (5) Patients with conditions such as cardiogenic shock, refractory heart failure, severe valvular insufficiency or stenosis, infective endocarditis, uncontrolled malignant tumors, pulmonary embolism, or other urgent and critical conditions. (6) Patients with severe non-cardiac chest pain. (7) Patients with a history of coronary artery bypass graft surgery. (8) Patients concurrently using other Chinese herbal preparations or participating in other research projects. (9) Patients taking dual antiplatelet therapy. (10) Patients on long-term anticoagulant therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of angina attacks per week;Number of emergency medications per week; | — |
Secondary
| Measure | Time frame |
|---|---|
| Absolute value or percentage of monocytes (Mono);IL-17;IL-6;CCS angina score;SF-36 Quality of Life score;Chest tightness chest pain TCM symptom score;Electrocardiogram;Clinical efficacy evaluation;Single cell sequencing analysis; | — |
Countries
China
Contacts
Public ContactLiu Qingqing
Guangdong Provincial Hospital of Chinese Medicine Zhuhai Hospital
Outcome results
None listed